TWI367213B - Variants of c-type natriuretic peptide - Google Patents
Variants of c-type natriuretic peptideInfo
- Publication number
- TWI367213B TWI367213B TW097145167A TW97145167A TWI367213B TW I367213 B TWI367213 B TW I367213B TW 097145167 A TW097145167 A TW 097145167A TW 97145167 A TW97145167 A TW 97145167A TW I367213 B TWI367213 B TW I367213B
- Authority
- TW
- Taiwan
- Prior art keywords
- variants
- natriuretic peptide
- type natriuretic
- type
- peptide
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/58—Atrial natriuretic factor complex; Atriopeptin; Atrial natriuretic peptide [ANP]; Cardionatrin; Cardiodilatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/2242—Atrial natriuretic factor complex: Atriopeptins, atrial natriuretic protein [ANP]; Cardionatrin, Cardiodilatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cardiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Endocrinology (AREA)
- Molecular Biology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Hospice & Palliative Care (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Vascular Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US98949707P | 2007-11-21 | 2007-11-21 | |
US6148808P | 2008-06-13 | 2008-06-13 |
Publications (2)
Publication Number | Publication Date |
---|---|
TW200927758A TW200927758A (en) | 2009-07-01 |
TWI367213B true TWI367213B (en) | 2012-07-01 |
Family
ID=40364250
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TW097145167A TWI367213B (en) | 2007-11-21 | 2008-11-21 | Variants of c-type natriuretic peptide |
Country Status (10)
Country | Link |
---|---|
US (1) | US8377884B2 (en) |
EP (1) | EP2217620A2 (en) |
JP (1) | JP2011504506A (en) |
AR (1) | AR069409A1 (en) |
AU (1) | AU2008326327A1 (en) |
CA (1) | CA2705603A1 (en) |
CL (1) | CL2008003476A1 (en) |
PE (1) | PE20091067A1 (en) |
TW (1) | TWI367213B (en) |
WO (1) | WO2009067639A2 (en) |
Families Citing this family (54)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PL1759001T3 (en) | 2004-04-21 | 2011-09-30 | Alexion Pharma Inc | Bone delivery conjugates and method of using same to target proteins to bone |
PL2432489T3 (en) | 2009-05-20 | 2017-05-31 | Biomarin Pharmaceutical Inc. | Variants of c-type natriuretic peptide |
JP2011026294A (en) * | 2009-06-26 | 2011-02-10 | Canon Inc | Compound |
KR101226165B1 (en) | 2009-07-23 | 2013-01-24 | 가부시키가이샤 이기스 | Composition for external preparation for skin |
KR20130001337A (en) | 2009-08-27 | 2013-01-03 | 쿄고 엔도 | Therapeutic agent for rhinitis |
RU2636738C2 (en) * | 2009-09-25 | 2017-11-28 | Шайр Орфан Терапис ГмбХ | New npr-b agonists |
AR078446A1 (en) | 2009-12-18 | 2011-11-09 | Alcon Res Ltd | NPR-B AGONISTS. USE. |
WO2011075471A2 (en) * | 2009-12-18 | 2011-06-23 | Alcon Research, Ltd. | Novel npr-b agonists and methods of use for the treatment of c-type natriuretic peptide-mediated disorders |
US20110300071A1 (en) * | 2010-06-04 | 2011-12-08 | Washington University | Targeting npr-c in angiogenesis and atherosclerosis with a c-type atrial natriuretic factor (canf)-comb nanocomplex |
WO2012088608A1 (en) | 2010-12-27 | 2012-07-05 | Enobia Canada Limited Partnership | Compositions comprising natriuretic peptides and methods of use thereof |
CN103547282A (en) | 2011-01-21 | 2014-01-29 | Igisu株式会社 | Therapeutic agent for alopecia |
US20140072557A1 (en) | 2011-02-28 | 2014-03-13 | National Cerebral And Cardiovascular Center | Medicinal agent for suppressing malignant tumor metastasis |
US9233143B2 (en) | 2011-08-19 | 2016-01-12 | National Cerebral And Cardiovascular Center | Medicinal agent for preventing exacerbation of malignant tumor, comprising combination of natriuretic peptide receptor GC-A and GC-B agonists |
WO2013058833A1 (en) | 2011-10-19 | 2013-04-25 | Enobia Canada Limited Partnership | Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof |
EP2794646A4 (en) * | 2011-12-23 | 2015-12-09 | Mayo Foundation | Assessing renal structural alterations and outcomes |
WO2013161895A1 (en) | 2012-04-25 | 2013-10-31 | 第一三共株式会社 | Bone repair promoter |
US10052366B2 (en) | 2012-05-21 | 2018-08-21 | Alexion Pharmaceuticsl, Inc. | Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof |
CA2882881A1 (en) | 2013-03-10 | 2014-09-18 | National University Corporation Nagoya University | Therapeutic agent for systemic bone disease and use thereof |
CN106232141A (en) * | 2014-02-27 | 2016-12-14 | 第三共株式会社 | For the medicine by the growth deficiency giving steroid induction |
WO2016007873A1 (en) | 2014-07-11 | 2016-01-14 | The Regents Of The University Of Michigan | Compositions and methods for treating craniosynostosis |
AU2015357551B2 (en) | 2014-12-05 | 2021-02-25 | Alexion Pharmaceuticals, Inc. | Treating seizure with recombinant alkaline phosphatase |
AU2016205968A1 (en) * | 2015-01-09 | 2017-07-13 | Ascendis Pharma Growth Disorders A/S | CNP prodrugs |
AU2016211447B2 (en) | 2015-01-28 | 2021-09-23 | Alexion Pharmaceuticals, Inc. | Methods of treating a subject with an alkaline phosphatase deficiency |
JP6882256B2 (en) | 2015-07-30 | 2021-06-02 | バイオマリン ファーマシューティカル インコーポレイテッド | Use of C-type natriuretic peptide variants to treat skeletal dysplasia |
KR20180029255A (en) * | 2015-07-31 | 2018-03-20 | 가부시키가이샤 이기스 | CNP cyclic peptides and medicines, external preparations and cosmetics containing the cyclic peptides |
WO2017031114A1 (en) | 2015-08-17 | 2017-02-23 | Alexion Pharmaceuticals, Inc. | Manufacturing of alkaline phosphatases |
US11229686B2 (en) | 2015-09-28 | 2022-01-25 | Alexion Pharmaceuticals, Inc. | Reduced frequency dosage regimens for tissue non-specific alkaline phosphatase (TNSALP)-enzyme replacement therapy of hypophosphatasia |
US11400140B2 (en) | 2015-10-30 | 2022-08-02 | Alexion Pharmaceuticals, Inc. | Methods for treating craniosynostosis in a patient |
RU2759679C2 (en) * | 2015-12-08 | 2021-11-16 | Байомарин Фармасьютикал Инк. | Use of options of natriuretic peptide of type c for treatment of osteoarthritis |
KR102518217B1 (en) * | 2016-01-08 | 2023-04-04 | 아센디스 파마 그로우쓰 디스오더스 에이/에스 | Controlled-release cnp agonists with low npr-c binding |
US10835578B2 (en) * | 2016-01-08 | 2020-11-17 | Ascendis Pharma Growth Disorders A/S | CNP prodrugs with large carrier moieties |
AU2017205688C1 (en) * | 2016-01-08 | 2022-03-10 | Ascendis Pharma Growth Disorders A/S | Cnp prodrugs with carrier attachment at the ring moiety |
MX2018008050A (en) * | 2016-01-08 | 2018-08-23 | Ascendis Pharma Growth Disorders As | Controlled-release cnp agonists with increased nep stability. |
NZ743488A (en) * | 2016-01-08 | 2023-02-24 | Ascendis Pharma Growth Disorders As | Controlled-release cnp agonists with low initial npr-b activity |
AU2017205273C1 (en) * | 2016-01-08 | 2022-12-01 | Ascendis Pharma Growth Disorders A/S | Controlled-release CNP agonists with reduced side-effects |
US11065306B2 (en) | 2016-03-08 | 2021-07-20 | Alexion Pharmaceuticals, Inc. | Methods for treating hypophosphatasia in children |
WO2017173413A1 (en) | 2016-04-01 | 2017-10-05 | Alexion Pharmaceuticals, Inc. | Treating muscle weakness with alkaline phosphatases |
WO2017173395A1 (en) | 2016-04-01 | 2017-10-05 | Alexion Pharmaceuticals, Inc. | Methods for treating hypophosphatasia in adolescents and adults |
US20190218274A1 (en) * | 2016-05-06 | 2019-07-18 | Phasebio Pharmaceuticals, Inc. | Elp fusion proteins for controlled and sustained release |
US10988744B2 (en) | 2016-06-06 | 2021-04-27 | Alexion Pharmaceuticals, Inc. | Method of producing alkaline phosphatase |
EP3500289A4 (en) | 2016-08-18 | 2020-05-06 | Alexion Pharmaceuticals, Inc. | Methods for treating tracheobronchomalacia |
AU2017336253B2 (en) * | 2016-09-29 | 2023-02-23 | Ascendis Pharma Growth Disorders A/S | Combination therapy with controlled-release CNP agonists |
EP3574913A4 (en) | 2017-01-24 | 2020-07-22 | Daiichi Sankyo Company, Limited | Therapeutic agent for short stature |
WO2018175534A1 (en) * | 2017-03-22 | 2018-09-27 | Pharmain Corporation | Npra agonists, compositions, and uses thereof |
KR20190129058A (en) | 2017-03-31 | 2019-11-19 | 알렉시온 파마슈티칼스, 인코포레이티드 | How to treat hypophosphatase (HPP) in adults and adolescents |
JP2021519590A (en) | 2018-03-30 | 2021-08-12 | アレクシオン ファーマシューティカルズ, インコーポレイテッド | Glycoprotein production |
EP3553079A1 (en) * | 2018-04-12 | 2019-10-16 | Bayer Aktiengesellschaft | C-type natriuretic peptide engrafted antibodies |
BR112021014495A2 (en) | 2019-02-11 | 2021-11-23 | Ascendis Pharma Growth Disorders As | Dry pharmaceutical formulations of cnp conjugates |
CN111848776B (en) * | 2020-08-31 | 2022-03-18 | 江苏璟泽生物医药有限公司 | Polyethylene glycol modified rhBNP and preparation method thereof |
EP4366758A1 (en) | 2021-07-09 | 2024-05-15 | BioMarin Pharmaceutical Inc. | C-type natriuretic peptide variants to treat skeletal dysplasia in children |
TW202334188A (en) * | 2021-12-07 | 2023-09-01 | 美商拜奧馬林製藥公司 | Cnp therapy |
CA3236278A1 (en) * | 2021-12-13 | 2023-06-22 | Kennett Sprogoe | Effective doses of cnp conjugates |
WO2023227505A1 (en) | 2022-05-23 | 2023-11-30 | Ascendis Pharma Growth Disorders A/S | Liquid pharmaceutical formulations of cnp compounds |
WO2024094747A1 (en) * | 2022-11-02 | 2024-05-10 | Novo Nordisk A/S | Cnp compounds |
Family Cites Families (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK0478797T3 (en) * | 1990-04-20 | 1995-06-26 | Hisayuki Matsuo | Enjoy physiologically active peptide derived from pigs |
JP2930380B2 (en) | 1990-07-13 | 1999-08-03 | 壽之 松尾 | New bioactive peptide derived from pig (CNP-53) |
JP3026351B2 (en) | 1990-07-13 | 2000-03-27 | 壽之 松尾 | Porcine CNP gene and precursor protein |
JP3026354B2 (en) | 1990-09-27 | 2000-03-27 | 壽之 松尾 | Human CNP gene and precursor protein |
US5252714A (en) | 1990-11-28 | 1993-10-12 | The University Of Alabama In Huntsville | Preparation and use of polyethylene glycol propionaldehyde |
JP2809533B2 (en) | 1991-01-31 | 1998-10-08 | 壽之 松尾 | CNP analog peptide |
WO1994020534A1 (en) * | 1993-03-03 | 1994-09-15 | Mayo Foundation For Medical Education And Research | Vasonatrin peptide and analogs thereof |
US5665704A (en) * | 1993-11-12 | 1997-09-09 | Genentech, Inc. | Receptor specific atrial natriuretic peptides |
US5846932A (en) | 1993-11-12 | 1998-12-08 | Genentech, Inc. | Receptor specific atrial natriuretic peptides |
US5917019A (en) * | 1997-02-13 | 1999-06-29 | The Rockefeller University | Altered telomere repeat binding factor 2 |
US6136040A (en) | 1998-03-05 | 2000-10-24 | Washington University | Animal model with disrupted FGF-9 gene |
IL125958A0 (en) | 1998-08-27 | 1999-04-11 | Yeda Res & Dev | Animal model for fibroblast growth factor receptor associated chondrodysplasia |
WO2000061631A1 (en) | 1999-04-12 | 2000-10-19 | Astrazeneca Ab | Modified pentapeptide antagonists of the atrial natriuretic peptide clearance receptor |
US6887470B1 (en) * | 1999-09-10 | 2005-05-03 | Conjuchem, Inc. | Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components |
US6407211B1 (en) * | 1999-12-17 | 2002-06-18 | Mayo Foundation For Medical Education And Research | Chimeric natriuretic peptides |
IL142118A0 (en) * | 2001-03-20 | 2002-03-10 | Prochon Biotech Ltd | Method and composition for treatment of skeletal dysplasias |
BRPI0203172B8 (en) | 2001-09-28 | 2021-05-25 | Nakao Kazuwa | pharmaceutical composition for achondroplasia |
US7648962B2 (en) * | 2002-11-26 | 2010-01-19 | Biocon Limited | Natriuretic compounds, conjugates, and uses thereof |
ATE459370T1 (en) | 2002-11-26 | 2010-03-15 | Biocon Ltd | MODIFIED NATRIURETIC COMPOUNDS, CONJUGATES AND USES THEREOF |
EP3446711A1 (en) | 2004-03-31 | 2019-02-27 | Kazuwa Nakao | Composition for increasing body height |
US8455438B2 (en) * | 2008-12-29 | 2013-06-04 | Mayo Foundation For Medical Education And Research | Natriuretic polypeptides for reducing or preventing restenosis |
WO2012088608A1 (en) * | 2010-12-27 | 2012-07-05 | Enobia Canada Limited Partnership | Compositions comprising natriuretic peptides and methods of use thereof |
-
2008
- 2008-11-21 US US12/744,079 patent/US8377884B2/en not_active Expired - Fee Related
- 2008-11-21 AR ARP080105079A patent/AR069409A1/en unknown
- 2008-11-21 CA CA2705603A patent/CA2705603A1/en not_active Abandoned
- 2008-11-21 EP EP08851395A patent/EP2217620A2/en not_active Withdrawn
- 2008-11-21 TW TW097145167A patent/TWI367213B/en not_active IP Right Cessation
- 2008-11-21 WO PCT/US2008/084270 patent/WO2009067639A2/en active Application Filing
- 2008-11-21 AU AU2008326327A patent/AU2008326327A1/en not_active Abandoned
- 2008-11-21 CL CL2008003476A patent/CL2008003476A1/en unknown
- 2008-11-21 JP JP2010535081A patent/JP2011504506A/en not_active Withdrawn
- 2008-11-24 PE PE2008001957A patent/PE20091067A1/en not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
US20100331256A1 (en) | 2010-12-30 |
PE20091067A1 (en) | 2009-08-12 |
WO2009067639A2 (en) | 2009-05-28 |
WO2009067639A3 (en) | 2009-07-09 |
WO2009067639A4 (en) | 2009-09-11 |
US8377884B2 (en) | 2013-02-19 |
CL2008003476A1 (en) | 2009-08-14 |
JP2011504506A (en) | 2011-02-10 |
AU2008326327A1 (en) | 2009-05-28 |
EP2217620A2 (en) | 2010-08-18 |
TW200927758A (en) | 2009-07-01 |
CA2705603A1 (en) | 2009-05-28 |
AR069409A1 (en) | 2010-01-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HUS2200004I1 (en) | Variants of c-type natriuretic peptide | |
TWI367213B (en) | Variants of c-type natriuretic peptide | |
HK1135136A1 (en) | Natriuretic polypeptides | |
HK1170941A1 (en) | Oxyntomodulin peptide analogue | |
HK1170943A1 (en) | Oxyntomodulin peptide analogue | |
EP2150811A4 (en) | Human b-type natriuretic peptide assay having reduced cross-reactivity with other peptide forms | |
GB0723712D0 (en) | Peptides | |
GB0920981D0 (en) | Peptides | |
EP2270141A4 (en) | Partial peptide of lacritin | |
EP2123666A4 (en) | Peptide | |
EP2376919A4 (en) | Combined natriuretic peptide assays | |
GB0908515D0 (en) | Peptide | |
ZA201203722B (en) | Peptide | |
HK1152717A1 (en) | Angiogenic peptide | |
GB0703945D0 (en) | Peptide | |
GB0920987D0 (en) | Peptides | |
GB0812586D0 (en) | Chimaeric peptide | |
GB0817978D0 (en) | Peptides | |
GB0723337D0 (en) | Peptide with reduced dimer formation | |
EP2123751A4 (en) | Novel peptide | |
GB0800373D0 (en) | A peptide | |
GB0705115D0 (en) | Peptides | |
GB0707626D0 (en) | Peptides | |
GB0705251D0 (en) | Peptides | |
GB0815673D0 (en) | Peptides |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM4A | Annulment or lapse of patent due to non-payment of fees |